Late relapses in Hodgkin lymphoma: a clinical and immunohistochemistry study

Leukemia & Lymphoma
Mariano ProvencioCarmen Bellas

Abstract

Survival in Hodgkin lymphoma (HL) has significantly increased, and most relapses occur in the first 2 years. We analyzed the proportion of relapses occurring after 5 years, the method of detection, and survival in the database of patients with HL in our hospital (1967-2005). We undertook a retrospective study of clinical and molecular characteristics with the use of 12 different antibodies (Abs): CD30, CD15, CD20, CD3, BCL-2, BCL-6, CD57, EMA, p53, Ki-67, Aurora kinase A, and PAX-5. We studied 534 patients with HD and found 150 relapses (28%), 30 of which occurred 5 years after the end of treatment. The relapses were detected during a scheduled appointment in 16 (54%) asymptomatic patients. Seven of 30 patients relapsed with a different histological type. There were no statistically significant differences in survival between those patients with a late relapse and new remission and those who never relapsed. None of the molecular markers were associated with relapse. Long-term survival was not significantly different in relapsed patients with remission after treatment compared with patients who never relapsed. We need to maintain active follow-up in order to detect late and recoverable relapses.

References

Nov 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T A ListerM Tubiana
Feb 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S BodisJ Thomas
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas JostingAndreas Engert
Apr 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michal SieniawskiAndreas Josting
Nov 28, 2007·Journal of Clinical and Experimental Hematopathology : JCEH·Christos Emmanouilides
Feb 21, 2008·European Journal of Haematology·Martin Hutchings, Lena Specht
Aug 14, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mariano ProvencioFélix Bonilla

❮ Previous
Next ❯

Citations

Oct 15, 2013·British Journal of Haematology·Graham P CollinsKarl S Peggs
Feb 28, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul J BröckelmannAndreas Engert
Feb 23, 2018·Journal of Cancer Research and Clinical Oncology·László PinczésÁrpád Illés
Jun 15, 2013·American Journal of Clinical Pathology·Willemina R R Geurts-GieleAnton W Langerak

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.